General Information

CHA Medication Safety Guidelines for Fentanyl Patch

Despite warnings from the Food and Drug Administration, manufacturers and various patient safety agencies, fentaNYL transdermal patches continue to be prescribed inappropriately to treat patients with acute pain who are not opioid tolerant. CDPH has issued several Immediate Jeopardy administrative penalties for inappropriate use of fentaNYL transdermal patches.

Recognizing this as an ongoing issue, the CHA Medication Safety Committee created a High Alert Medication Guideline - FentaNYL Transdermal Patch, which is attached. The guideline summarizes safe-use practices; however, it should be considered only a guideline. Hospitals should consult with their hospital pharmacy and therapeutics committee prior to implementing the guideline.